Doximity and OpenEvidence settle dueling lawsuits over physician AI tools
Physician in the Loop, Oct 20, 2026
Listen to this post
read by AI voices ยท all episodesTHE SHORT READ
Doximity and OpenEvidence dismissed all claims in their federal lawsuit over physician AI tools, ending a case in which OpenEvidence accused Doximity staff of posing as physicians, Fierce Healthcare reported Oct. 19.
The claims and counterclaims were dismissed with prejudice, and each company bears its own costs and fees; the joint notice disclosed no other terms. Separately, Oxford researchers reported a labor-onset model that pairs clinical risk factors with computerized fetal heart tracing, and a BMJ review found that trials of large language model tools often leave out model versions, code and harms. The day brought few other developments.
THE DETAILS
- FYIIncident Oct 19, 2026OpenEvidence sued in June 2025 in the U.S. District Court for the District of Massachusetts, alleging that Doximity executives and employees impersonated physicians, used National Provider Identifier credentials to reach its platform and used prompt-injection techniques to try to extract confidential information such as system prompts, Fierce Healthcare reported. Doximity denied the allegations and counterclaimed for false advertising, unfair and deceptive practices and defamation. The parties reached a settlement in principle and filed a dismissal with prejudice, with each bearing its own costs and fees; no dollar amount was reported. Sarah Tishler, a Beck Reed Riden partner not involved in the case, said the litigation could have helped define the legal limits of AI competitive intelligence and prompt-injection attacks.
- FYIEvidence Oct 15, 2026Oxford researchers combined seven clinical risk factors, including maternal age, pre-eclampsia, diabetes and thick meconium, with five features extracted by computer from the first 20 minutes of cardiotocography, and validated the model, Fit4Labour, on births in Oxford, Cambridge and Sweden's Stockholm-Gotland region. At a 15% screen-positive rate its sensitivity for severe fetal compromise was 33.4%, against 39.9% for a clinical benchmark, a difference that was not statistically significant (p=0.18), the authors reported. In the Oxford 2020-24 validation set, severe compromise occurred in 0.9% of the highest-risk group and 0.1% of the lowest. The study was retrospective, and the authors said the model could produce interpretable output in real time.Sources: The Lancet Digital Health, PubMed record
- FYIEvidence Oct 13, 2026Researchers led by Dr. Danielle Bitterman of Mass General Brigham reviewed 68 trial reports, 15 protocols and 378 registrations for trials of large language model interventions published from 2017 through Dec. 6, 2025. Mean reporting completeness among trial reports was 40% against TRIPOD-LLM, 44% against CONSORT 2025 and 59% against CONSORT-AI, and registrations scored 61% against the World Health Organization's dataset, the authors reported. Model versioning, inference settings, access to protocols, data and code, and the planning and reporting of harms were inconsistently reported, which the authors said limits appraisal of safety before clinical use. Most trial reports were small, single-site randomized studies published in 2024 and 2025, many on patient education and management recommendations.Sources: BMJ, PubMed record
- FYIMoney Oct 19, 2026The London company, founded by neurosurgeon Dr. Ali Haddad, said its SurgicalOS platform is designed to work with existing scopes and navigation systems and remains in development, MobiHealthNews reported Oct. 19. The seed round was led by Playground Global, and former Medtronic chief executive Omar Ishrak was named board chair. The company said its technology has been used in more than 100 surgical cases on three continents, with live-procedure evaluations run under research governance while standard systems guided clinical decisions. XRlabs plans to seek regulatory authorization in the United Kingdom, Europe and the United States; no clearance has been reported.Source: MobiHealthNews
- FYIDeployment Oct 19, 2026The companies plan a package that combines structural and functional MRI, vascular imaging and CT to assess candidates, identify neural targets, plan surgery, guide navigation and confirm implant position, Fierce Biotech reported Oct. 19. The first focus is speech-motor function, with hand motor control and language restoration after stroke envisioned later. No financial terms, timeline or FDA submission were disclosed. "BCI performance begins before an implant ever reaches the brain," said Matt Angle, Paradromics' founder and chief executive.Source: Fierce Biotech